Fig. 6

Gal4 morpholino allows bypassing of early developmental stages.

(A?F) Embryos resulting from an incross between Tg[ET(hsp:Gal4VP16^s1001t);UAS:Kaede] double trangenics (A,D) or from Tg[ET(hsp:Gal4VP16^s1001t);UAS:Kaede] with Tg[UAS:N^ICD-Myc] animals (B?C, E?F) were either non-injected (NI, A?B, D?E) or injected with 3 ng of Gal4 MO (C,F). Representative specimens are depicted at 3 dpf. The lower panel shows a magnification of the different specimens after DiASP treatment (D?F). (G?J) Embryos resulting from a cross between Tg[ET(hsp:Gal4VP16^s1006t)] and Tg[UAS:N^ICD-Myc] animals were either non-injected (G and magnification in H) or injected with 3 ng of Gal4 MO (I and magnification in J). Representative specimens are depicted at 6 dpf. (K?P) Embryos resulting from a cross between Tg[hspGFF53A;UAS:EGFP] double transgenic animals and either wt (K, N) or Tg[UAS:N^ICD-Myc] (L?M, O?P) animals were either non-injected (K?L, N?O) or injected with 3 ng of Gal4 MO (M, P). Representative specimens are depicted at 7 dpf. (K?M) Maximal projections of posterior lateralis afferent ganglion (dashed circles) and central projection (white arrowheads). (N?P) Maximal projections of posterior lateralis afferent nerve. (Scale bars: 150 μm for A?F, H and J; 300 μm for G and I; 100 μm for K?P).